Outcomes of surgical bioprosthetic aortic valve replacement in patients ≤65 and >65 years of age

Affiliations

Aurora St. Luke's Medical Center

Abstract

BACKGROUND: Implantation of a bioprosthetic valve is a reasonable choice for patients aged >65 years. For middle-aged patients, there is less certainty about whether a mechanical or bioprosthetic valve is best. METHODS: The PERIcardial SurGical AOrtic Valve ReplacemeNt (PERIGON) Pivotal Trial is evaluating the safety and efficacy of the Avalus bioprosthesis. We evaluated clinical and echocardiographic outcomes through 5 years of follow-up, stratified by age ≤65 and >65 years. RESULTS: Two hundred seventy-one patients (24.2%) were ≤65 years old, and 847 (75.8%) were >65 years old. Most patients in both groups were male (217 [80.1%] vs 623 [73.6%], respectively; p=0.031). Younger patients had a lower STS risk of mortality (1.1±0.9% vs 2.2±1.4%, p65 years of age.

Document Type

Article

PubMed ID

35065064


 

Share

COinS